FLSM
RYTM icon

Frazier Life Sciences Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Frazier Life Sciences Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-678,760
Closed -$36M – 54
2025
Q1 		$36M Sell
678,760
-1,191,048
-64% -$66.1M 1.64% 14
2024
Q4 		$105M Sell
1,869,808
-547,144
-23% -$30.2M 4.34% 8
2024
Q3 		$127M Buy
2,416,952
+45,648
+2% +$2.19M 5.08% 6
2024
Q2 		$97.4M Buy
2,371,304
+181,125
+8% +$7.23M 4.55% 6
2024
Q1 		$94.9M Sell
2,190,179
-181,125
-8% -$7.93M 4% 8
2023
Q4 		$109M Hold
2,371,304
– – 5.83% 6
2023
Q3 		$54.4M Buy
2,371,304
+204,082
+9% +$4.57M 3.61% 8
2023
Q2 		$35.7M Buy
2,167,222
+2,483
+0.1% +$44.8K 2.13% 11
2023
Q1 		$38.6M Buy
2,164,739
+270,739
+14% +$6.8M 2.8% 11
2022
Q4 		$55.2M Hold
1,894,000
– – 3.43% 12
2022
Q3 		$46.4M Buy
+1,894,000
New +$35.2M 3.57% 8

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Frazier Life Sciences Management's RYTM Position: Q2 2025 in Review

Frazier Life Sciences Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 678,760 shares — an estimated $36M sold.

Frazier Life Sciences Management first reported a position in RYTM in Q3 2022 and held it in 11 quarters. The position peaked at $127M in Q3 2024. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • Frazier Life Sciences Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 678,760 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $36M.
  • Frazier Life Sciences Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Frazier Life Sciences Management's Rhythm Pharmaceuticals position peaked at $127M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Frazier Life Sciences Management's 13F filing for Q2 2025, filed 14 Aug 2025.